Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation

for the Worldwide Network for Blood & Marrow Transplantation

doi:10.1016/j.jtct.2020.11.019

Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation

for the Worldwide Network for Blood & Marrow Transplantation

Medicine - Hematology, Oncology, Transplant

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Abstract

SARS-CoV-2 has spread rapidly worldwide, but the full impact of the COVID-19 pandemic on the field of hematopoietic cell transplantation (HCT) remains unknown. To understand this better, an 18-item online survey was disseminated by the Worldwide Network for Blood & Marrow Transplantation with questions exploring SARS-CoV-2 testing algorithms, mobilization, and cryopreservation strategies and COVID-19 infections in allogeneic related and autologous hematopoietic progenitor cell (HPC) donors. The aim of this survey was to assess the impact of the outbreak on policies relating to HPC mobilization, collection, and processing with respect to changes in daily routine. A total of 91 individual responses from distinct centers in 6 continents were available for analysis. In these centers, the majority (72%) of allogeneic related and autologous donors are routinely tested for SARS-CoV-2 before HPC collection, and 80% of centers implement cryopreservation of allogeneic HPC grafts before commencing conditioning regimens in patients. Five related and 14 autologous donors who tested positive for COVID-19 did not experience any unexpected adverse events or reactions during growth factor administration (eg, hyperinflammatory syndrome). These data are limited by the small number of survey respondents but nonetheless suggest that centers are following the recommendations of appropriate scientific organizations and provide some preliminary data to suggest areas of further study.

Original language	English (US)
Pages (from-to)	270.e1-270.e6
Journal	Transplantation and Cellular Therapy
Volume	27
Issue number	3
DOIs	https://doi.org/10.1016/j.jtct.2020.11.019
State	Published - Mar 2021

Bibliographical note

Funding Information:
The authors thank Martine Schuit for translating the questionnaire into the SurveyGizmo tool and distributing the link. The authors are grateful to all centers who participated and thank all staff members at the various institutions for their support. Financial disclosure: There are no financial dislosures to report in the context of the submitted manuscrip. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: N.W. B.S. M.A. M.K. A.S. D.W. J.S. S.G. Y.K. P.E. S.H. Y.A. J.S. W.S. D.N. and H.G. designed the survey and wrote the manuscript, and N.W. analyzed the data.

Publisher Copyright:
© 2020 The American Society for Transplantation and Cellular Therapy

Keywords

COVID-19
Cryopreservation
G-CSF
Mobilization

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1016/j.jtct.2020.11.019

OpenUrl availability

Full text

Cite this

@article{99f2a25f66634cb2ad608cc03fc307dd,

title = "Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation",

abstract = "SARS-CoV-2 has spread rapidly worldwide, but the full impact of the COVID-19 pandemic on the field of hematopoietic cell transplantation (HCT) remains unknown. To understand this better, an 18-item online survey was disseminated by the Worldwide Network for Blood & Marrow Transplantation with questions exploring SARS-CoV-2 testing algorithms, mobilization, and cryopreservation strategies and COVID-19 infections in allogeneic related and autologous hematopoietic progenitor cell (HPC) donors. The aim of this survey was to assess the impact of the outbreak on policies relating to HPC mobilization, collection, and processing with respect to changes in daily routine. A total of 91 individual responses from distinct centers in 6 continents were available for analysis. In these centers, the majority (72%) of allogeneic related and autologous donors are routinely tested for SARS-CoV-2 before HPC collection, and 80% of centers implement cryopreservation of allogeneic HPC grafts before commencing conditioning regimens in patients. Five related and 14 autologous donors who tested positive for COVID-19 did not experience any unexpected adverse events or reactions during growth factor administration (eg, hyperinflammatory syndrome). These data are limited by the small number of survey respondents but nonetheless suggest that centers are following the recommendations of appropriate scientific organizations and provide some preliminary data to suggest areas of further study.",

keywords = "COVID-19, Cryopreservation, G-CSF, Mobilization",

author = "{for the Worldwide Network for Blood & Marrow Transplantation} and Nina Worel and Shaw, {Bronwen E.} and Mahmoud Aljurf and Mickey Koh and Adriana Seber and Daniel Weisdorf and Joseph Schwartz and Sebastian Galeano and Yoshihisa Kodera and Eldridge, {Paul W.} and Shahrukh Hashmi and Yoshiko Atsuta and Jeff Szer and Wael Saber and Dietger Niederwieser and Greinix, {Hildegard T.}",

note = "Funding Information: The authors thank Martine Schuit for translating the questionnaire into the SurveyGizmo tool and distributing the link. The authors are grateful to all centers who participated and thank all staff members at the various institutions for their support. Financial disclosure: There are no financial dislosures to report in the context of the submitted manuscrip. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: N.W. B.S. M.A. M.K. A.S. D.W. J.S. S.G. Y.K. P.E. S.H. Y.A. J.S. W.S. D.N. and H.G. designed the survey and wrote the manuscript, and N.W. analyzed the data. Publisher Copyright: {\textcopyright} 2020 The American Society for Transplantation and Cellular Therapy",

year = "2021",

month = mar,

doi = "10.1016/j.jtct.2020.11.019",

language = "English (US)",

volume = "27",

pages = "270.e1--270.e6",

journal = "Transplantation and Cellular Therapy",

issn = "2666-6367",

publisher = "Elsevier BV",

number = "3",

}

TY - JOUR

T1 - Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19

T2 - A Survey from the Worldwide Network for Blood & Marrow Transplantation

AU - for the Worldwide Network for Blood & Marrow Transplantation

AU - Worel, Nina

AU - Shaw, Bronwen E.

AU - Aljurf, Mahmoud

AU - Koh, Mickey

AU - Seber, Adriana

AU - Weisdorf, Daniel

AU - Schwartz, Joseph

AU - Galeano, Sebastian

AU - Kodera, Yoshihisa

AU - Eldridge, Paul W.

AU - Hashmi, Shahrukh

AU - Atsuta, Yoshiko

AU - Szer, Jeff

AU - Saber, Wael

AU - Niederwieser, Dietger

AU - Greinix, Hildegard T.

N1 - Funding Information: The authors thank Martine Schuit for translating the questionnaire into the SurveyGizmo tool and distributing the link. The authors are grateful to all centers who participated and thank all staff members at the various institutions for their support. Financial disclosure: There are no financial dislosures to report in the context of the submitted manuscrip. Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: N.W. B.S. M.A. M.K. A.S. D.W. J.S. S.G. Y.K. P.E. S.H. Y.A. J.S. W.S. D.N. and H.G. designed the survey and wrote the manuscript, and N.W. analyzed the data. Publisher Copyright: © 2020 The American Society for Transplantation and Cellular Therapy

PY - 2021/3

Y1 - 2021/3

N2 - SARS-CoV-2 has spread rapidly worldwide, but the full impact of the COVID-19 pandemic on the field of hematopoietic cell transplantation (HCT) remains unknown. To understand this better, an 18-item online survey was disseminated by the Worldwide Network for Blood & Marrow Transplantation with questions exploring SARS-CoV-2 testing algorithms, mobilization, and cryopreservation strategies and COVID-19 infections in allogeneic related and autologous hematopoietic progenitor cell (HPC) donors. The aim of this survey was to assess the impact of the outbreak on policies relating to HPC mobilization, collection, and processing with respect to changes in daily routine. A total of 91 individual responses from distinct centers in 6 continents were available for analysis. In these centers, the majority (72%) of allogeneic related and autologous donors are routinely tested for SARS-CoV-2 before HPC collection, and 80% of centers implement cryopreservation of allogeneic HPC grafts before commencing conditioning regimens in patients. Five related and 14 autologous donors who tested positive for COVID-19 did not experience any unexpected adverse events or reactions during growth factor administration (eg, hyperinflammatory syndrome). These data are limited by the small number of survey respondents but nonetheless suggest that centers are following the recommendations of appropriate scientific organizations and provide some preliminary data to suggest areas of further study.

AB - SARS-CoV-2 has spread rapidly worldwide, but the full impact of the COVID-19 pandemic on the field of hematopoietic cell transplantation (HCT) remains unknown. To understand this better, an 18-item online survey was disseminated by the Worldwide Network for Blood & Marrow Transplantation with questions exploring SARS-CoV-2 testing algorithms, mobilization, and cryopreservation strategies and COVID-19 infections in allogeneic related and autologous hematopoietic progenitor cell (HPC) donors. The aim of this survey was to assess the impact of the outbreak on policies relating to HPC mobilization, collection, and processing with respect to changes in daily routine. A total of 91 individual responses from distinct centers in 6 continents were available for analysis. In these centers, the majority (72%) of allogeneic related and autologous donors are routinely tested for SARS-CoV-2 before HPC collection, and 80% of centers implement cryopreservation of allogeneic HPC grafts before commencing conditioning regimens in patients. Five related and 14 autologous donors who tested positive for COVID-19 did not experience any unexpected adverse events or reactions during growth factor administration (eg, hyperinflammatory syndrome). These data are limited by the small number of survey respondents but nonetheless suggest that centers are following the recommendations of appropriate scientific organizations and provide some preliminary data to suggest areas of further study.

KW - COVID-19

KW - Cryopreservation

KW - G-CSF

KW - Mobilization

UR - http://www.scopus.com/inward/record.url?scp=85101114408&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85101114408&partnerID=8YFLogxK

U2 - 10.1016/j.jtct.2020.11.019

DO - 10.1016/j.jtct.2020.11.019

M3 - Article

C2 - 33781537

AN - SCOPUS:85101114408

SN - 2666-6367

VL - 27

SP - 270.e1-270.e6

JO - Transplantation and Cellular Therapy

JF - Transplantation and Cellular Therapy

IS - 3

ER -

Changes in Hematopoietic Cell Transplantation Practices in Response to COVID-19: A Survey from the Worldwide Network for Blood & Marrow Transplantation

Abstract

Bibliographical note

Keywords

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this